STOCK TITAN

180 Life Sciences Corp. - $ATNF STOCK NEWS

Welcome to our dedicated page for 180 Life Sciences news (Ticker: $ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 180 Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 180 Life Sciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.66%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.75%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.36%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.86%
Tags
none
180 Life Sciences Corp.

Nasdaq:ATNF

ATNF Rankings

ATNF Stock Data

1.71M
765.12k
3.35%
11.2%
4.97%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PALO ALTO

About ATNF

180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.